It can contribute to the deterioration of prognosis in breast cancer patients by interacting with CCR3 and can also interact with CCR5 to affect the progression and metastasis of hepatocellular carcinoma (Singh et al., 2020; Yamaguchi et al., 2021). This evidence concerns the gene CCR3 and breast carcinoma.